GSK PLC - Benlysta granted Orphan Drug Designation by US FDA

RNS Number: 4982 O GSK PLC 01 February 2023 Issued: 1 February 2023, London UK. Benlysta granted Orphan Drug Designation by US FDA for the potential treatment of systemic sclerosis. GSK plc today announced that the US Food and Drug Administration has granted Orphan Drug Designation to Benlysta, a B-cell inhibiting monoclonal antibody, for the potential...